SEATTLE, Nov. 19, 2010 (GLOBE NEWSWIRE) -- Attorney Advertising. Keller Rohrback L.L.P. (http://www.globenewswire.com/newsroom/ctr?d=125152&u=http://www.seattleclassaction.com">www.krclassaction.com) announces that it is investigating heart rhythm abnormalities associated with the use of Darvon and Darvocet, prescription pain medications. Both Darvon and Darvocet, which contain propoxyphene, are manufactured and marketed by Xanodyne Pharmaceuticals Inc.
Recently, Xanodyne agreed to withdraw Darvon and Darvocet from the market in response to a request from the Food and Drug Administration ("FDA"). The FDA submitted its request to Xanodyne, and to generic manufacturers of the drug, after reviewing data from a new trial study that focused on propoxyphene's affect on heart rhythms. According to the statement issued by the FDA: "The drug's effectiveness in reducing pain is no longer enough to outweigh the drug's serious potential heart risks."
If you or someone you know was injured as a result of taking Darvon or Darvocet, or you would like more information regarding this investigation, please contact attorney Michael Woerner at (800) 776-6044 or via email at info@kellerrohrback.com.
Keller Rohrback, with offices in Seattle, Phoenix, and New York, has extensive experience with pharmaceutical litigation, including cases involving the diet drugs Fen-Phen and Redux, as well as Propulsid and Vioxx medications. The efforts of the firm's trial lawyers have resulted in consumers recovering tens of millions of dollars.
Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.